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Abstract
Purpose The purpose of the study is to systematically review
and synthesise randomised controlled trials investigating the
effectiveness of prehabilitation compared to usual care for
newly diagnosed, adult-onset cancer patients.
Methods MEDLINE, EMBASE, PsycINFO, CINAHL and
SSCI were searched up to April 2017. Studies were included
if disease-related, treatment-related, patient-reported and
health service utilisation outcomes were assessed. Two re-
viewers independently reviewed and appraised the risk of bias
of each study.
Results Eighteen studies were included. Interventions com-
prised one or more of the following components: psycholog-
ical support, education and exercise. Meta-analyses found that
pelvic floor muscle training (PFMT) significantly increased
odds of continence at 3 months (OR = 3.29, 95% CI = 1.57–
6.91), but did not significantly reduce daily pad use at
6 months post-surgery Mean Difference (MD)= ( = − 0.96,
95% CI = − 2.04–0.12) for prostate cancer patients. Although
quality of life improved due to PFMT, functional ability or
distress did not. Further meta-analyses indicated that pre-
surgical exercise significantly reduced length of hospital stay
(MD = − 4.18, 95% CI = − 5.43–− 2.93) and significantly
lowered odds of post-surgery complications (OR = 0.25, 95%
CI = 0.10–0.66) for lung cancer patients. Psychology-based
prehabilitation significantly improved mood, physical well-
being and immune function for prostate cancer patients and
improved fatigue and psychological outcomes and a trend for
better quality of life among breast cancer patients. Risk of bias
was high for most studies.
Conclusions Prehabilitation appears to benefit cancer pa-
tients. Rigorous trials are needed to investigate the effective-
ness of prehabilitation among other cancer sites and other
related effects. The cost-effectiveness of prehabilitation re-
mains unanswered.
Implications for cancer survivors Providing interventions ear-
lier in the care pathway may lead to better outcomes for pa-
tients during survivorship.
Keywords Cancer . Prehabilitation . Systematic review .
Meta-analysis
Introduction
Cancer is a major global health problem, with most recent
estimates reporting 14.1 million new cancer cases worldwide
in 2012 [1]. Although treatments are becomingmore effective,
resulting in decreased mortality from cancer, cancer and can-
cer treatment remain challenging for patients and their fami-
lies. Recently diagnosed cancer patients experience a range of
emotional responses and uncertainty about what to expect
from treatment [2, 3] and are at risk of developing physical,
psychological and social ‘late consequences’ as a result of
cancer and its treatment [4]. These changes have a detrimental
effect on patients’ lives in domains such as returning to work,
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family relationships, activities of daily living and, generally,
quality of life (QoL) [4–6]. It is important to investigate strat-
egies that might maximise support for patients during the pre-
treatment period given the increasing number of individuals
living for longer with cancer and consequentially with its
effects.
The period between cancer diagnosis and treatment pre-
sents a unique opportunity to support and prepare patients
for treatment. This pre-treatment or prehabilitation phase pro-
vides cancer patients with a programmatic way, potentially, to
prepare physically and psychologically for cancer treatment
and the challenges of ‘survivorship’. More specifically, there
may be significant beneficial effects for patients in terms of
developing coping resources and skills and improving recov-
ery from cancer treatment. In turn, the benefits of a
prehabilitation programme may lead to an appropriate reduc-
tion in the use of health services and a maximisation of post-
treatment physical and psychological outcomes [7, 8]. This
systematic review aims to assess the effectiveness of cancer
prehabilitation interventions versus standard care on physical,
psychological and health service utilisation outcomes.
Methods
This review was conducted in accordance with Cochrane
Collaboration methods [9] and reported according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analysis (PRISMA) checklist [10]. The following
sou r ces we re s ea r ched : EMBASE, MEDLINE,
PsycINFO, Cumulative Index of Nursing and Allied
Health Literature (CINAHL) and Social Sciences Citation
Index (SSCI) up to 3 April 2017 (see Supplementary Fig. 1
for search strategy). The eligibility criteria were applied
independently to the titles, abstracts and subsequently full
texts of each paper by two reviewers (CT and TK). A third
reviewer (MD) was available in the event that no consen-
sus was reached. The citation lists of identified reviews and
included studies were also searched and citations assessed
for eligibility. The review is registered on PROSPERO (ID
CRD42016036072).
Eligibility criteria
Randomised controlled trials (RCTs) which compared one or
more prehabilitation interventions to standard or usual care
were included in the review. Prehabilitation interventions were
defined according to the following criteria: baseline assess-
ment of patients; initiation prior to acute treatment with cura-
tive treatment (chemotherapy, radiotherapy or surgery) for
newly diagnosed, adult-onset cancer patients; and aimed to
have an impact on physical, or psychological health and health
service utilisation outcomes. Interventions which continued
during or after treatment were included [11]. The following
intervention types were excluded: pharmacological interven-
tions delivered in isolation or in combination with non-
pharmacological interventions and pre-operative procedures
occurring within hours of treatment. Studies including patients
with benign tumours were included only if outcome data were
reported separately for benign and malignant tumour groups.
Study populations with secondary or metastatic cancers were
excluded.
Data extraction, synthesis and risk of bias assessment
Data were extracted independently by two reviewers (CT and
TK) (see Supplementary Table 1 for study characteristics).
Data were examined for suitability to be included in a meta-
analysis. Some data could be pooled statistically using
Cochrane Collaboration’s Review Manager (RevMan) ver-
sion 5.3 using random effects models. Heterogeneity was
assessed using the I2 statistic. The remaining data were syn-
thesised narratively. The following aspects of each study were
assessed for risk of bias using the Cochrane Collaboration risk
of bias tool [9]: random sequence generation, allocation con-
cealment, participant and personnel blinding, outcome
blinding, incomplete outcome assessment and selective out-
come reporting. Risk of bias was assessed independently by
two reviewers (CT and TK); a third reviewer (MD) was avail-
able to settle any non-consensus. Risk of bias for each study
was categorised as follows: (i) low if all criteria were scored as
low risk of bias, (ii) moderate if one or two criteria were scored
as unclear or high risk of bias and (iii) high if more than two
criteria were scored at unclear or high risk of bias. We consid-
ered studies of all levels of methodological quality and decid-
ed to include less robust studies because of the sparseness of
the literature and in order to maximise potential lessons from
the review.
Results
A total of 18 studies were included in the review (see supple-
mentary Fig. 2 for study eligibility). One paper reported the
findings of two intervention studies [12], and two papers re-
ported different outcomes regarding the same intervention
[13, 14]. Studies were conducted in the USA (n = 8), Italy
(n = 3), the UK (n = 1), the Netherlands (n = 1), Turkey
(n = 1), Australia (n = 1), Switzerland (n = 1), China (n = 1)
and Denmark (n = 1). A total of 1381 patients were enrolled
across the studies including individuals with lung cancer
(n = 7), prostate cancer (n = 5), breast cancer (n = 4) bladder
cancer (n = 1) and multiple cancer sites (n = 1).
J Cancer Surviv (2018) 12:64–73 65
The majority of interventions were implemented prior to
surgery; one study was implemented before radiotherapy [15].
Interventions were implemented 1 to 2 weeks (n = 9), 1 to
5 days (n = 2), 1 month (n = 2), 3 weeks (n = 1) and the day
preceding treatment (n = 1). Three studies did not specify the
time frame of intervention implementation prior to treatment
[16–18]. Standard care varied according to individual institu-
tions whereby verbal or written instructions were given [15,
19–21], physical activity was delivered in the rehabilitation
setting post-treatment [22, 23], generic risk management and
active mobilisation was given [18] or fast-track surgery was
implemented [24]. Five studies delivered interventions in the
pre-treatment period only [12, 17, 18, 25–27]; the remaining
studies continued the interventions during or after treatment.
In total, 22 interventions were compared to a usual care con-
trol group. The interventions included pelvic floor muscle
training (PFMT) with biofeedback (n = 4), psychological in-
terventions (n = 4), education (n = 4), pulmonary rehabilita-
tion (n = 4), physical activity (n = 3), gown (n = 1) and
combined gown and education intervention (n = 1). Two psy-
chological interventions were compared to ‘attentional’ con-
trol groups [13, 14, 23]. The intensity of intervention delivery
varied between the studies including 2 contacts (n = 4), 1
single contact (n = 3), 10 contacts (n = 2), 20 contacts
(n = 2), 6 contacts (n = 1), 15 contacts (n = 1), 14 contacts
(n = 1), 4 contacts (n = 1), 3 sessions (n = 1), 2 to 3 contacts
per week (n = 1) and 6 sets of daily exercises over a 7-day
period (n = 1).
Risk of bias
Fourteen studies were scored as having high risk of bias; two
studies were scored as having moderate risk of bias, and a
further two studies were scored as having low risk of bias
(see Supplementary Fig. 3). There was evidence of selective
or incomplete outcome reporting within the studies. The
randomisation process, allocation concealment and blinding
processes were poorly described in many of the studies.
Prostate cancer
PFMT versus usual care
Four studies investigated the effects of PFMT versus usual
care on continence-related outcomes [16, 19, 21, 28], QoL
[21, 28], lifestyle and functional ability [21] and satisfaction
[28]. Studies were rated as having high [16, 21], moderate [19]
and low [28] risk of bias.
A meta-analysis of three studies (of low, moderate and high
risk of bias ratings, respectively) [16, 19, 28] indicated that
patients who undertook PFMT were over three times
significantly more likely than patients who received usual care
to recover urinary continence at 3 months post-surgery
(OR = 3.29, 95% CI = 1.57–6.91, I2 = 15%) (see Fig. 1).
The following continence-related results emanate from indi-
vidual studies which could not be combined in a meta-
analysis unless stated otherwise. For example, at 1 month
post-treatment, there was a significant benefit on recovery of
continence for patients undertaking PFMT compared to con-
trols (intervention (IV) 44.1% (n = 26) versus control (C)
20.3% (n = 12), p = 0.018) [28]. Compared to controls, patients
who underwent PFMT had significantly shorter median time to
continence recovery (IV 12 weeks versus C 16 weeks,
p < 0.05) [16]. At 1 and 6 months post-treatment, there was a
significant benefit of PFMT on the proportion of patients who
achieved continence compared to the control group (6 versus
0, p = 0.02; 10 versus 1, p = 0.002, respectively) [19]. A further
study found that men who underwent PFMTwere significantly
quicker to recover continence at 6 months post-surgery com-
pared to controls (KaplanMeier log rank: p = 0.04). Moreover,
at 6 months, there was 20.03% difference in proportion of men
who recovered continence in the intervention and control
groups, favouring the intervention group [21].
Findings from individual studies report that at 1 and 3months
post-treatment, the PFMT group had around a 60% reduced
odds of being incontinent compared to the control group
(OR = 0.41, 95% CI = 0.20–0.84, p = 0.016 and OR = 0.38,
95% CI = 0.18–0.79, respectively) [28]. The control group ex-
perienced significantly more incontinence episodes compared to
the intervention group at 3 months (IV 3.84 versus C 13.06,
p = 0.01) and 6 months (IV 2.72 versus C 13.06, p = 0.005),
but not at 1 month post-treatment [19]. Participants in one study
underwent a 24-h pad weight test as an indication of inconti-
nence, at both 1 and 3-month follow-up. Significantly fewer
participants who underwent PFMT had a pad > 150 g compared
to controls (IV 25.4% versus C 33.9%, p = 0.04 and IV 16.9
versus C 32.2, p = 0.033, respectively) [28].
Two studies (with a moderate and a high risk of bias rating,
respectively) [19, 21] were combined in a meta-analysis, and
this analysis pointed to a trend for improvement among
patients who underwent PFMTcompared to usual care regard-
ing daily pad use 6 months post-surgery (Mean Difference
(MD)= − 0.96, 95% CI = − 2.04–0.12, I2 = 90%)
(see Fig. 2). One study found that at 1 year post-surgery, one
patient in each group used between one and three pads daily;
three patients (15.8%) in the control group and two patients
(10.5%) used more than three pads daily [16].
At 6 months post-intervention, a significantly lower pro-
portion of participants in the intervention group compared to
the control group had severe/continual leakage (IV = 5.9%
versus C = 19.6%, p = 0.04).Moreover, the intervention group
spent significantly more days without leaks (IV = 72.6 versus
C = 54.2, p = 0.04) [21]. There were significant between-
group differences (favouring the intervention group) in
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survey-assessed overactive bladder and urinary function at
3 months (IV 10.12 versus C 13.19, p = 0.04 and IV 403.81
versus C 272.44, p = 0.006, respectively) and 6 months (IV
9.06 versus C 12.62, p = 0.01 and IV 422.50 versus C 274.25,
p = 0.003, respectively), but not 1 month post-treatment [19].
Compared to patients who underwent PFMT, patients who
received usual care were significantly more likely to experi-
ence episodes of urine loss due to coughing (n = 11 versus
n = 24, p = 0.003), sneezing (n = 13 versus n = 23, p = 0.02)
and getting up from a lying down position (n = 7 versus
n = 15, p = 0.04) [21]. There were no significant between-
group differences on other reasons for urine loss (e.g. due to
lifting or walking) [21].
A meaningful meta-analysis could not be conducted for the
remaining outcomes for PFMT versus usual care due to het-
erogeneity. So, findings from individual studies are reported in
narrative form. There were no significant between-group dif-
ferences in proportion of patients who returned to work or
resumed usual activities or in lifestyle factors, distress or
QoL [21]. Continence-related QoL was significantly im-
proved in the intervention compared to the control group at
1 month (IV 14.6 versus C 18.3, p = 0.002) and 3 months (IV
8.1 versus C 12.2, p = 0.002) post-treatment [28]. Patterns of
continence-related QoL varied according to whether patients
were completely dry, occasionally incontinent or incontinent.
The significant between-group difference favouring the inter-
vention group remained at 3 months post-treatment for pa-
tients who were dry after 2 months (IV 3.8 versus C 5.5,
p < 0.001). A significant benefit in incontinence-related QoL
for the intervention group compared to the control group
remained at 1 month (IV 14.5 versus C 16.2, p = 0.006) and
3 months (IV 8.5 versus C 10.5, p = 0.014) for patients who
were occasionally incontinent. There was a significant im-
provement in incontinence-related QoL (favouring the inter-
vention group) at 1 month (IV 21.9 versus C 25.9, p ≤ 0.001),
but not 3 months (IV 22.2 versus C 22.3, p = 0.886) post-
treatment among patients who were incontinent [28].
Seventy-five percent of patients in the PFMT intervention
reported feeling extremely satisfied with the intervention [28].
Psychological intervention versus usual care
One study (reported in two reports) investigated the effects of
stress management training (SMT) versus supportive attention
(SA) and standard care on psychological [13], QoL [13], bio-
logical [14], health service utilisation [13] and post-operative
complication [13] outcomes among prostate cancer patients.
This study was rated as having high risk of bias [13, 14]. The
effect of SMT versus SA and standard care on mood distur-
bance measured using the Profile of Mood States (POMS) at
1 week pre, and morning of, surgery was assessed using gen-
eralised linear mixed models controlling for several factors. A
significant main effect for group (p = 0.02) and time (p = 0.04)
was found with the SMT group having lower levels of mood
disturbance over time and compared to the standard care
group. There was an absence of a group by time interaction
for mood disturbance [14]. The significant between-group dif-
ferences were not sustained in the long term from 6-week to
12-month follow-up. Trial findings indicate that there were no
significant between-group or within-group differences with
regards to scores on the Impact of Events Scale. Only the
Physical Component Summary (PCS) score of the SF-36
demonstrated a significant between-group difference
(p < 0.004) and significant changes over time at 6 weeks,
6 months and 12 months (p < 0.02), with the SMT group
reporting better physical well-being than the standard care
group. A significant group by time interaction was absent
for PCS scores. Significant changes over the course of the
interventionwere observed for various domains of the prostate
cancer-specific QoL including urinary function (p < 0.0001),
Fig. 1 PFMT versus usual care on recovery of continence among prostate cancer patients 3 months post-surgery
Fig. 2 PFMT versus usual care on daily pad use among prostate cancer patients at 6 months post-surgery
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limitation (p < 0.0001), bother (p < 0.0001), sexual function
(p < 0.0001) and cancer worry (p < 0.004). A decline in scores
for each domain was observed from baseline to 6 weeks and
6 months post-surgery and an increase by 12 months post-
surgery. There were no significant group by time interactions
for prostate cancer-specific QoL [13].
Immunological markers were collected at baseline, 1month
prior to surgery and 48 h post-surgery. Natural killer cell cy-
totoxicity (NKCC) levels were significantly higher in the
SMT group compared to both SA and standard care groups
(levels in both groups decreased, whilst levels in the SMT
group increased) at the 80:1 peripheral blood mononuclear
cell (PBMC) effector (E) and K562 cell line target (T) ratio
(p = 0.04) and a trend for significance for the 40:1 E/T
(p = 0.06). Pro-inflammatory markers, interleukin (IL)-
12p70, IL-1 beta (β) and tumour necrosis factor alpha
(TNF-α) were significantly higher in the SMT group com-
pared to the SA group (p = 0.028, p = 0.018 and p = 0.05,
respectively). Only IL-1β was significantly higher (p = 0.05)
in the SMT group compared to the standard care group. There
was a trend for higher IL-8 levels (p = 0.06) in the SMT group
compared to the other groups. There were no between-group
differences between the SA and standard care groups [14].
There was an absence of between-group differences in
surgery-related problems and other complications and fre-
quency of hospital admissions until the end of follow-up at
12 months [13].
Lung cancer
Pre-surgical exercise versus usual care
Seven studies investigated the effects of pre-surgical exercise
compared to usual care on health service utilisation [12, 17,
18, 22], post-operative complications [12, 17, 18, 22], cardio-
pulmonary [12, 17, 18, 22, 25], QoL [17] and psychological
[26] outcomes among lung cancer patients. Each study was
rated as having a high risk of bias.
Findings from three studies [12, 17, 22] were combined in
a meta-analysis which indicated a significant benefit for pre-
surgical pulmonary exercise versus usual care on the total
number of days spent in the hospital among lung cancer pa-
tients (MD = − 4.20, 95% CI = − 5.45–− 2.95, I2 = 0%) (see
Fig. 3). Findings from individual studies on other health ser-
vice utilisation outcomes reported a reduction in the number
of days spent in hospital post-operation (pulmonary
prehabilitation [mean = 4.4] compared to the usual care group
[mean = 6.9], p = 0.010) [17]. Furthermore, high-intensity
interval training (HIIT) led to a significant reduction in hours
spent in recovery from anaesthesia (median = 25 versus 17,
p < 0001) compared to patients who did not participate in
HIIT; however, there was no significant between-group
difference for days spent in hospital [18]. There were no sig-
nificant between-group differences for mean number of inten-
sive care unit hours or mean ventilation hours as a result of
pulmonary exercise [12]. There were significantly fewer lung
cancer patients in the pre-operative exercise group who expe-
rienced prolonged chest intubation (n = 1 versus n = 5,
p = 0.03) and had significantly fewer mean number of days
with a chest tube (4.3 (sd = 2.1) versus 8.8 (sd = 5.30),
p = 0.04) compared to patients who received usual care [12].
Ameta-analysis combining findings from three studies [12,
17, 22] found benefits for pre-surgical exercise compared to
usual care for post-operative complications among lung can-
cer patients (OR = 0.25, 95% CI = 0.10–0.66, I2 = 0%) (see
Fig. 4). Results from individual studies that could not be in-
cluded in the meta-analysis found that the incidence of respi-
ratory complications was lower among patients who partici-
pated in HIIT compared to usual care. There were no signifi-
cant between-group differences in cardiovascular and surgical
complications, wound infection or renal dysfunction as a re-
sult of HIIT [18]. Regarding specific complications, a control
group in one study [22] experienced fever (n = 2), atelectasis
(n = 1), pneumonia (n = 1) and haemorrhagic drainage (n = 1),
whereas fever was experienced by one patient in the interven-
tion group. In a further study [17], grade 1 (n = 15 versus
n = 16), grade 2 (n = 4 versus n = 8), grade 3 (n = 2 versus
n = 4), grade 4 (n = 0 versus n = 1) and grade 5 (n = 0 versus
n = 1) complications were experienced by the intervention and
control groups, respectively. There were no significant
between-group differences in the proportion of patients with
respiratory failure, pneumonia or atelectasis in an additional
study [12].
Findings could not be combined in a meta-analysis for car-
diopulmonary outcomes, so the following results refer to indi-
vidual studies. In one study, from pre-intervention to post-in-
tervention, the intervention group experienced significant im-
provements in forced expiratory volume (FEV1) (p < 0.001),
forced volume capacity (FVC) (p = 0003), carbon monoxide
diffusion capacity (DLCO) (p < 0.001) and partial arterial ox-
ygen pressure (PaO2) (p < 0001) and a significant decrease in
partial arterial carbon dioxide pressure (PaCO2) (p = 0.004)
[22]. A further study of elderly patients found significant
between-group differences in peak expiratory flow, but not
DLCO, FEV1 and FVC post-intervention [17]. A study inves-
tigating the effects of HIIT found improvements in peak oxy-
gen volume (VO2) (p = 0.004) and peak work rate (p = 0.021),
but no other differences in other cardiopulmonary measures
compared to the usual care group were found [18].
Participants with lung cancer and comorbid chronic obstruc-
tive pulmonary disease (COPD) who received a pre-operative
pulmonary rehabilitation programme (versus usual care) had
significantly increased peak volume oxygen (VO2) levels on
the day of surgery (p < 0.0001) and 60 days post-surgery
(p < 0.005). However, significant between-group differences
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in pulmonary function (FEV1) were not observed at any time
point [25]. There was a significant beneficial effect of exercise
on total heart rate (p = 0.04) [22], walking distance ((p < 0.001)
[22], (p = 0.001) [18], (p = 0.029) [17]), walking speed
(p < 0.001) [22] and walking duration (p < 0.001) [22] com-
pared to usual care. In a further study, there were no significant
between-group differences in the shuttle walk test [12].
An exercise intervention combining respiratory, arm, leg,
walking and stair climbing exercises was compared to a usual
care group on hope and empowerment measures. There were
no significant between-group or within-group differences in
hope over the course of the trial. A significant benefit in power
for the intervention group was found from pre-intervention to
post-intervention (t = − 2.68, p = 0.01), but not from post-
intervention to 4 to 6 days post-surgery (t = − 1.89, p = 0.07).
However, a significant increase in power from pre-intervention
to 4 to 6 days post-surgery (t = − 3.73, p = 0.001) was observed
for the exercise group. There was a significant decrease in
power from pre-intervention to post-intervention (t = 2.72,
p < 0.01) for the control group, and power decreased (albeit
not significantly so) from post-intervention to 4 to 6 days post-
surgery (t = − 0.29, p = 0.78) [26]. ANOVA models indicated
that there was a significant between-group difference post-
intervention (F(1, 143) = 4.77, p = 0.03) and 4 to 6 days
post-intervention (F(1, 143) = 11.13, p < 0.01) favouring a
beneficial improvement in power for the exercise group.
Bonferroni-corrected t tests indicated significant increase in
power from pre-intervention to post-intervention (t = − 2.68,
p = 0.01) and pre-intervention to shortly after surgery
(t = − 2.68, p = 0.01) for the intervention group. This improve-
ment was not significant from post-intervention to shortly after
surgery. A different pattern of power emerged for participants
in the control group whereby power decreased over time but
was only significant from pre-intervention to post-intervention
(t = 2.72, p = 0.009) [26].
One study measured the effect of pulmonary prehabilitation
on QoL outcomes with no benefits for patients [17].
One trial was terminated early due to slow recruitment
(under-powered sample); interim analysis found that there
were no significant between-group differences in any out-
come. The trial was deemed to be infeasible as patients were
reluctant to delay treatment to participate in the trial [12].
Breast cancer
Psychosocial intervention versus usual care
Three studies investigated the effectiveness of psychosocial
interventions compared to usual care on a range of somatic
[23, 29], biological markers [27] and psychological outcomes
[23, 27, 29]. Each study was rated as having high risk of bias.
In one study, breast cancer patients scheduled to receive
surgery were allocated to a psychotherapeutic intervention
group, two attentional control groups or a usual care group.
However, the investigation of intervention effectiveness was
limited because the usual care group was not assessed on
outcome measures pre-operation. An intervention effect on
recovery or physiological indices was not observed [23]. A
study investigated the effects of a psychosocial intervention
(including psychoeducation about stress, problem-solving and
relaxation skills and supportive discussion) compared to usual
care on immunological markers and psychological variables.
The study found no significant interaction or main effect of
time or group allocation on NKCC levels. However, there was
a significant group by time allocation interferon gamma
(IFNγ) indicating maintenance of IFNγ levels among patients
in the intervention group and a decrease of IFNγ levels among
the control group. A significant between-group difference was
observed pre-intervention, and therefore, an ANCOVAmodel
Fig. 4 Pre-surgical exercise versus usual care on post-surgical complications among lung cancer patients
Fig. 3 Pre-surgical pulmonary exercise versus usual care on number of days spent in hospital among lung cancer patients
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was undertaken to control for pre-intervention IFNγ levels.
The ANCOVA model did not indicate or retain a significant
group by time interaction [27].
Intervention and attentional control groups observed sig-
nificant benefits for distress-related body image compared to
controls at 3 months and 1 year post-surgery (F = 12.3,
p = 0.0006). The control group (compared to participants in
any of the other groups) had significantly higher levels of
distress (p = 0.024), anxiety and depression (p = 0.005) as
assessed by questionnaire at 3 months post-surgery. One year
post-surgery, significantly higher levels of distress related to
loss of breast (p = 0.004), partner’s response and total worries
were found for controls compared to intervention participants.
The control group was less likely to report fighting spirit as a
coping approach and were more likely to have caseness for
anxiety or depression (25 versus 10%) [23]. The interest sub-
scale (F = 20.1, df = 1.24, p < 0.0003) and enjoyment subscale
of the Differential Emotions Scale (DES) (F = 15.4, df = 1.24,
p < 0.0003) increased over time from pre-intervention to post-
intervention, whereas the sadness subscale (F = 7.2, df = 1.24,
p = 0.01) decreased over time for the intervention group. A
significant group by time interaction was found for DES dis-
gust, whereby disgust increased and decreased over time for
the control and intervention and attentional control groups,
respectively. There were no significant main effects for the
remaining eight emotions measured by this scale. A signifi-
cant main effect from pre-intervention to post-intervention for
the Life Orientation Test (LOT) measuring optimism was
found (F = 4.6, df = 1.27, p < 0.05). There were no significant
benefits of the intervention versus control group in optimism,
depression or Impact of Events Scale (IES) [27].
Breast cancer patients were randomised to a SMT group or
usual care. Significant between-group differences at 5 days
post-surgery were observed for depression and 2 and 5 days
post-surgery for fatigue, whereby the SMT group reported a
decrease in both outcomes. There were no significant
between-group differences in anxiety, QoL, perceived control
or sleep. Patients in SMT group experienced an improvement
in QoL at days 2 and 30 post-surgery, and both groups expe-
rienced a reduction in anxiety over time [29].
Education and papilla gown versus usual care
One study (rated as having high risk of bias) investigated ed-
ucation, Papilla gown and combined education and Papilla
gown interventions with usual care of a standard hospital gown
on activity levels, cancer knowledge, body image, lymphede-
ma and comfort levels for breast cancer patients [20].
Activity levels increased over time for patients (p < 0.001),
patients who wore the Papilla gown compared to those who did
not had significantly higher levels of activity (Papilla gown
mean = 4.88 versus usual care mean = 4.59, p = 0.026). The
combined education and gown intervention did not lead to any
significant main effects or interactions for activity levels. One
week post-operation, use of the Papilla gown demonstrated a
beneficial effect on activity levels compared to participants
who did not wear the gown (Papilla gown mean = 4.50 versus
usual care mean = 4.21, p = 0.039). There was a significant
beneficial effect (p < 0.001) of education (mean = 0.34) com-
pared to no education (mean = 0.11) on cancer knowledge. A
significant interaction was found between education and wear-
ing the Papilla gown (p = 0.037). One week and 1 month post-
operation, participants in the Papilla gown group had a signif-
icant improvement in breast cancer knowledge compared to
participants who were not in the Papilla gown group (Papilla
gown mean = 0.27 versus usual care mean = 0.20, p < 0.001).
Similarly, receipt of education versus no education had a sig-
nificant improvement on breast cancer knowledge (education
mean = 0.36 versus no education mean = 0.11, p < 0.001).
Education only at 6 months post-operation was significantly
associated with improvement in breast cancer knowledge com-
pared to no education receipt (p = 0.014). Neither the Papilla
gown nor the education receipt had a significant effect on body
image for breast cancer patients.
Patients who wore the Papilla gown experienced signifi-
cantly more comfort compared to the usual care group (Papilla
gown mean = 4.41 versus usual care mean = 3.00, p < 0.001).
There was a beneficial effect of wearing the Papilla Gown
compared to the standard gown at 1 week (Papilla gown
mean = 4.46 versus usual care mean = 2.53, p < 0.001) and
an increase in comfort 6 months post-operation (p = 0.006) for
the Papilla gown group. There was a significantly lower inci-
dence of lymphedema among patients who wore the Papilla
gown compared to those who did not (p = 0.0097) from base-
line to post-intervention. Comfort levels significantly im-
proved over time from T1 to T2 for patients (p = 0.0004) [20].
Bladder cancer
One study (rated as having moderate risk of bias) compared a
standardised fast-track pathway to an intensive pre-operative
exercise intervention which continued post-operatively for pa-
tients treated with radical cystectomy. The study found no
significant benefits for patients in terms of length of hospital
stay (p = 0.68), complication incidents (p = 0.47), severity of
complications (p = 0.64), hospital readmissions (p = 0.49),
mortality (p = 0.84), bowel function restoration (p > 0.05),
energy intake (0.60) or protein intake (p = 0.29) [24].
Multiple cancer sites
One study (rated as having low risk of bias) investigated the
effects of a psychoeducational, cancer-related fatigue inter-
vention trial (CAN-FIT) guided by the Health Belief Model
to encourage self-care strategies to reduce fatigue among can-
cer patients [15].
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The intervention was delivered pre-radiotherapy only, post-
radiotherapy only or pre-radiotherapy and post-radiotherapy
and compared to usual care. There were no differences in fa-
tigue, QoL, depression, anxiety, physical activity levels or oc-
cupational activities between the CAN-FIT and usual care
groups. There were some group differences depending on
when the CAN-FIT intervention was delivered. Between base-
line and post-radiotherapy assessments, there was a significant
increase in moderate activity levels (β = 1.4, 95% CI = 0.53–
2.26) and vigorous activity levels (β = 1.05, 95% CI = 0.24–
1.86) and a significant decrease in QoL utility scores
(β = − 0.11, 95% CI = − 0.22–0.00) among participants who
received CAN-FIT pre-radiotherapy. A significant increase in
vigorous activity levels (β = 1.24, 95% CI = 0.44–2.03) and a
significant decrease in hours of paid work (β = − 0.72, 95%
CI = − 1.44–− 0.04) was found for participants who received
CAN-FIT pre-radiotherapy compared to those who did not
receive CAN-FIT pre-radiotherapy from baseline to 6-week
follow-up. Patients who did not receive CAN-FIT post-radio-
therapy experienced a beneficial effect on mental fatigue
(β = − 1.66, 95% CI = − 3.21–− 0.10) and QoL utility scores
(β = 0.10, 95% CI = 0.00–− 0.20). Moreover, patients who
received CAN-FIT post-radiotherapy walked significantly
more per week (β = 5.82, 95% CI = 0.07–11.56) and were
significantly more likely to participate in unpaid work
(β = 561.79, 95% CI = 51.21–1072.37) [15].
In terms of adherence to the intervention, 55% (range = 48–
66%) fully adhered to the intervention, 59% (range = 52–
66%) completed 75% of the intervention, 68% (range = 60–
74%) adhered to half of the intervention and 14% (range = 8–
18%) adhered to 30% of the intervention. Psychological fac-
tors (e.g. anxiety), somatic factors (e.g. pain, fatigue) and
acute side effects from procedures such as discomfort from
catheterisation were reported as reasons for not fully adhering
to the intervention [15].
Discussion
Clearly, there is a need to consider ways in which to maximise
treatment effectiveness, recovery and survival in the face of
the increasing number of individuals diagnosed with cancer
and the subsequent demands and pressure that this places on
healthcare systems and services. This review demonstrates
that prehabilitation may be one way in which to meet these
challenges as it appears, overall, to have several benefits for
patients. For example, PFMT improved urinary continence
outcomes and QoL for prostate cancer patients though there
were no improvements in functional ability or distress.
Psychological-based prehabilitation interventions led to im-
provedmood, better physical well-being and immune function
for prostate cancer patients, lower distress, depression, anxi-
ety, fatigue and emotional states and increased optimism and
fighting spirit, with a trend for better QoL among breast cancer
patients. Pre-operative exercise had several benefits for lung
cancer patients in terms of pulmonary function, functional
ability, health service utilisation and experience of treatment-
related complications, even for patients with comorbid ill-
nesses. Education interventions also demonstrated benefits
for patients. Although the effectiveness of prehabilitation on
QoL was not significant, trends in QoL improvements were
observed. It may be that interventions were not of sufficient
intensity to lead to clear sustained improvements in QoL and
‘booster’ sessions may be required. Perhaps, ceiling effects
regarding QoL may be present at this critical time point given
the nature of treatment that is received and related acute side
effects likely to be experienced by patients.
Few studies have addressed the effectiveness of delivering
interventions prior, as opposed, to following cancer treat-
ments. The CAN-FIT study did not find any additional bene-
fits of implementing a psychoeducation intervention pre-
radiotherapy compared to post-radiotherapy [15]. However,
enhanced benefits relating to urinary incontinence were found
for prehabilitative PFMT [19]. Other studies not included in
the review (because they did not meet one or more eligibility
criteria) found improved outcomes for patients in the
prehabilitation versus rehabilitation period, for example, com-
bined interventions for patients with colorectal (exercise, nu-
trition and counselling) [30] or lung cancer (exercise and nu-
trition) [31]. Pre-operative exercise for lung cancer patients
was associated with a number of benefits for patients [32].
Prehabilitative versus rehabilitative swallowing or respiratory
therapy led to significant benefits for patients with head and
neck cancers [33–35]. There appears to be a potentially sig-
nificant advantage to implementing prehabilitation rather than
rehabilitation interventions for cancer patients.
Most of the studies in the review did not investigate the
influence of prehabilitation on recurrence or survival out-
comes. Physical activity and exercise are beneficial in terms
of the primary and secondary prevention of cancer as well as
cancer-related and all-cause mortality [36]. Future research
should investigate the degree to which prehabilitation exercise
programmes as an adjunct to traditional cancer therapies pres-
ent an advantage for patients in terms of survival and
recurrence.
Usually, there is a short window of opportunity for
prehabilitation to be implemented prior to treatment. Time-
appropriate implementation coupled with patient anxiety and
uncertainty about what to expect from imminent treatment and
its outcomes is challenging for service delivery staff, patients
and families. According to results of the review, prehabilitation
appears to be acceptable to patients and feasible to implement
with good levels of adherence supported by studies within the
review [15, 18, 29]. This finding is further supported by the
wider research literature [37]. Even an intensive prehabilitation
exercise programme compared to home-based exercise was
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found to have good levels of adherence [38], as long as
prehabilitation did not interfere with receipt of cancer treatment
[12]. Other studies have found that exercise in the
prehabilitation period was feasible for sedentary individuals
[39]. The results from a single-case report hinted that
prehabilitation may be beneficial for elderly patients [40]
which, in turn, supported the findings by Lai et al. [17].
Study limitations
This review was guided by Cochrane Collaboration methods
and the PRISMA statement and has various strengths. Paper
selection, risk of bias assessment and data extraction were
undertaken independently, and the search included a range
of multi-disciplinary bibliographic databases. However, the
review did not include searches of the grey literature, non-
English language publications or non-randomised studies
which are potential limitations. Moreover, various included
studies were rated as having high risk of bias or had a small
number of trial participants. We decided not to exclude studies
of low methodological quality or with potentially underpow-
ered samples so as to give a comprehensive overview of the
nature and type of prehabilitation studies within cancer care.
Therefore, this fact should be borne in mind when considering
the results of the review.
Clinical implications
Global policy priorities recognise the need to plan and provide
long-term support for the increasing population of cancer sur-
vivors. In various countries, clinical guidelines have been de-
veloped to identify and address the psychosocial needs of
cancer survivors; and there is a concentrated drive to deliver
high-quality cancer survivorship care and to intervene appro-
priately at the point of diagnosis [41]. Whilst there is move-
ment towards the implementation of evidence-based interven-
tions in the period post-cancer treatment, there is a need to
research and consider recommending the implementation of
interventions in the prehabilitation period, as part of usual
care. The review findings presented here indicate that
prehabilitation may be potentially effective though further re-
search is required including studies of cost-effectiveness and
scope for appropriate reductions in health service utilisation,
less post-operative complications and improvements in QoL.
Studies from related fields point to the likelihood of the cost-
effectiveness of prehabilitation. For example, one study cal-
culated incremental cost-effectiveness ratios (ICERs) for pre-
treatment swallowing therapy and found that it was cost-
effective compared to swallowing therapy in the rehabilitative
period [42].
This is the first comprehensive systematic review to the
best of our knowledge that has addressed the full range of
prehabilitation interventions among cancer patients irrespec-
tive of cancer site. Mindful of the results of the risk of bias
analysis, there appear to be benefits to delivering interventions
to cancer patients during the prehabilitation period in terms of
reduced health service utilisation, reduced frequency and se-
verity of treatment-related effects and other important patient
outcomes. However, there is a need for rigorous trials to ex-
amine and test prehabilitation and its cost-effectiveness par-
ticularly among cancer sites other than breast, prostate or lung
cancer and to consider whether interventions delivered early
in the care pathway combat cancer-related effects such as pain,
sleep and cognitive changes.
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